CGNI fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Cardiogeni Plc engages in the discovery and development regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans on December 28, 2016 and is headquartered in Stratford-upon-Avon, the United Kingdom.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
CGNI has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company